Aura Biosciences (NASDAQ:AURA – Get Rating) released its quarterly earnings data on Wednesday. The company reported ($0.52) EPS for the quarter, beating analysts’ consensus estimates of ($0.58) by $0.06, Yahoo Finance reports.
Aura Biosciences Stock Down 1.3 %
Shares of AURA opened at $10.18 on Thursday. The firm’s 50 day simple moving average is $10.55 and its 200 day simple moving average is $12.32. Aura Biosciences has a 1-year low of $9.43 and a 1-year high of $24.83.
Analyst Upgrades and Downgrades
Separately, JMP Securities cut their price objective on shares of Aura Biosciences from $30.00 to $25.00 in a research report on Thursday.
Insider Activity at Aura Biosciences
Institutional Investors Weigh In On Aura Biosciences
Institutional investors and hedge funds have recently bought and sold shares of the stock. Morgan Stanley raised its stake in shares of Aura Biosciences by 17.1% during the fourth quarter. Morgan Stanley now owns 64,603 shares of the company’s stock worth $678,000 after acquiring an additional 9,451 shares in the last quarter. Alps Advisors Inc. purchased a new position in shares of Aura Biosciences during the fourth quarter worth approximately $257,000. Alyeska Investment Group L.P. purchased a new position in shares of Aura Biosciences during the fourth quarter worth approximately $225,000. Price T Rowe Associates Inc. MD purchased a new position in shares of Aura Biosciences during the fourth quarter worth approximately $7,762,000. Finally, Renaissance Technologies LLC purchased a new position in shares of Aura Biosciences during the fourth quarter worth approximately $138,000. 55.63% of the stock is owned by hedge funds and other institutional investors.
About Aura Biosciences
Aura Biosciences, Inc operates as a biotechnology company that develops therapies to treat cancer. The company develops virus-like drug conjugates (VDC) technology platform for the treat tumors of high unmet need in ocular and urologic oncology. It develops AU-011, a VDC candidate for the treatment of primary choroidal melanoma.
- Get a free copy of the StockNews.com research report on Aura Biosciences (AURA)
- This Is What To Expect From The Q2 Reporting Cycle
- 3 Chip Stocks Approaching Buy Points
- Don’t Overlook This Reliable, Dividend-Paying Sector
- Bearish Guidance at 3M, Still the Same Upside
- Is Credit Suisse On The Brink of a Collapse?
Receive News & Ratings for Aura Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aura Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.